Alvogen is a private, US-based pharmaceuticals company founded in 2009. Since 2015, it has been majority-owned by CVC Capital Partners and Temasek Holdings.[2] Alvogen focuses on so-called 'difficult-to-make' generic drugs and injectables, and both produces its own products and markets the products of brand name pharmaceutical companies.[3]
History
Alvogen was founded by Icelandic entrepreneur Róbert Wessman, who stepped down from his position as CEO of another generics company, Actavis, in order to found the company.[4][5]
The first and still a central component of Alvogen is the 130-year old